Citations

Showing 10 of 108094 citations.

Delayed onset sleep-related stridor due to radiation for thyroid cancer
McCarter, Stuart J. , Herold, Daniel L. , Kolla, Bhanu Prakash , McCarter, Stuart J , Mansukhani, Meghna P.

Mayo Clinic

Journal of Clinical Sleep Medicine | June 17, 2022 | Volume: 18 | Issue: 9 | Pages: 2327-2329

10.5664/jcsm.10128 | PMID 35713170 Get It

Eosinophils protect against acetaminophen‐induced liver injury through cyclooxygenase‐mediated IL‐4/IL‐13 production
Xu, Long , Yang, Yang , Jiang, Jiali, Wen, Yankai , Jeong, Jong‐Min , Emontzpohl, Christoph , Atkins, Constance L. , Kim, Kangho , Jacobsen, Elizabeth A. , Wang, Hua , Ju, Cynthia, Atkins, Constance Lynn , Jacobsen, Elizabeth A , Wen, Yankai , Yang, Yang , Kim, Kangho

Mayo Clinic

Hepatology | June 17, 2022 | Volume: 77 | Issue: 2 | Pages: 456-465

10.1002/hep.32609 | PMID 35714036 Get It

Background and Aims: A better understanding of the underlying mechanism of acetaminophen (APAP)‐induced liver injury (AILI) remains an important endeavor to develop therapeutic approaches. Eosinophils have been detected in liver biopsies of patients with APAP overdose. We recently demonstrated a profound protective role of eosinophils against AILI; however, the molecular mechanism had not been elucidated. Approach and Results: In agreement with our previous data from experiments using genetic deletion of eosinophils, we found that depletion of eosinophils in wild‐type (WT) mice by an anti‐IL‐15 antibody resulted in exacerbated AILI. Moreover, adoptive transfer of eosinophils significantly reduced liver injury and mortality rate in WT mice. Mechanistic studies using eosinophil‐specific IL‐4/IL‐13 knockout mice demonstrated that these cytokines, through inhibiting interferon‐γ, mediated the hepatoprotective function of eosinophils. Reverse phase protein array analyses and in vitro experiments using various inhibitors demonstrated that IL‐33 stimulation of eosinophils activated p38 mitogen‐activated protein kinase (MAPK), and in turn, cyclooxygenases (COX), which triggered NF‐κB–mediated IL‐4/IL‐13 production. In vivo adoptive transfer experiments showed that in contrast to naive eosinophils, those pretreated with COX inhibitors failed to attenuate AILI. Conclusions: The current study revealed that eosinophil‐derived IL‐4/IL‐13 accounted for the hepatoprotective effect of eosinophils during AILI. The data demonstrated that the p38 MAPK/COX/NF‐κB signaling cascade played a critical role in inducing IL‐4/IL‐13 production by eosinophils in response to IL‐33.
Optimizing the Breast Imaging Report for Today and Tomorrow
McGrath, Anika L. , Berg, Wendie A. , Mendelson, Ellen B., Drotman, Michele , Ellis, Richard L. , Berg, Wendie A , McGinty, Geraldine B. , Langlotz, Curtis P.

Mayo Clinic

Journal of Breast Imaging | June 17, 2022 | Volume: 4 | Issue: 4 | Pages: 343-345

10.1093/jbi/wbac033 | PMID 38416981 Get It

Multicenter Repeatability and Reproducibility of MR Fingerprinting in Phantoms and in Prostatic Tissue
Lo, Wei‐Ching , Bittencourt, Leonardo Kayat , Panda, Ananya , Jiang, Yun , Tokuda, Junichi , Tempany, Clare M. , Obmann, Verena Carola , Seiberlich, Nicole , Gulani, Vikas , Obmann, Verena , Seethamraju, Ravi Teja , Wright, Katherine, Griswold, Mark A.

Mayo Clinic

Magnetic Resonance in Medicine | June 17, 2022 | Volume: 88 | Issue: 4 | Pages: 1818-1827

10.1002/mrm.29264 | PMID 35713379 Get It

PurposeTo evaluate multicenter repeatability and reproducibility of T1 and T2 maps generated using MR fingerprinting (MRF) in the International Society for Magnetic Resonance in Medicine/National Institute of Standards and Technology MRI system phantom and in prostatic tissues.MethodsMRF experiments were performed on 5 different 3 Tesla MRI scanners at 3 different institutions: University Hospitals Cleveland Medical Center (Cleveland, OH), Brigham and Women's Hospital (Boston, MA) in the United States, and Diagnosticos da America (Rio de Janeiro, RJ) in Brazil. Raw MRF data were reconstructed using a Gadgetron‐based MRF online reconstruction pipeline to yield quantitative T1 and T2 maps. The repeatability of T1 and T2 values over 6 measurements in the International Society for Magnetic Resonance in Medicine/National Institute of Standards and Technology MRI system phantom was assessed to demonstrate intrascanner variation. The reproducibility between the 4 clinical scanners was assessed to demonstrate interscanner variation. The same‐day test–retest normal prostate mean T1 and T2 values from peripheral zone and transitional zone were also compared using the intraclass correlation coefficient and Bland–Altman analysis.ResultsThe intrascanner variation of values measured using MRF was less than 2% for T1 and 4.7% for T2 for relaxation values, within the range of 307.7 to 2360 ms for T1 and 19.1 to 248.5 ms for T2. Interscanner measurements showed that the T1 variation was less than 4.9%, and T2 variation was less than 8.1% between multicenter scanners. Both T1 and T2 values in in vivo prostatic tissue demonstrated high test–retest reliability (intraclass correlation coefficient > 0.92) and strong linear correlation (R2 > 0.840).ConclusionProstate MRF measurements of T1 and T2 are repeatable and reproducible between MRI scanners at different centers on different continents for the above measurement ranges.
Serum and Soleus Metabolomics Signature of Klf10 Knockout Mice to Identify Potential Biomarkers
Baroukh, Nadine , Canteleux, Nathan, Lefèvre, Antoine , Dupuy, Camille , Martias, Cécile , Presset, Antoine , Subramaniam, Malayannan , Hawse, John R. , Emond, Patrick , Pouletaut, Philippe , Morandat, Sandrine , Bensamoun, Sabine F. , Nadal‐Desbarats, Lydie , Nadal‐Desbarats, Lydie , Bensamoun, Sabine F , Nadal‐Desbarats, Lydie

Mayo Clinic

Metabolites | June 17, 2022 | Volume: 12 | Issue: 6 | Pages: 556

10.3390/metabo12060556 | PMID 35736488 Get It

The transcription factor Krüppel-like factor 10 (Klf10), also known as Tieg1 for TGFβ (Inducible Early Gene-1) is known to control numerous genes in many cell types that are involved in various key biological processes (differentiation, proliferation, apoptosis, inflammation), including cell metabolism and human disease. In skeletal muscle, particularly in the soleus, deletion of the Klf10 gene (Klf10 KO) resulted in ultrastructure fiber disorganization and mitochondrial metabolism deficiencies, characterized by muscular hypertrophy. To determine the metabolic profile related to loss of Klf10 expression, we analyzed blood and soleus tissue using UHPLC-Mass Spectrometry. Metabolomics analyses on both serum and soleus revealed profound differences between wild-type (WT) and KO animals. Klf10 deficient mice exhibited alterations in metabolites associated with energetic metabolism. Additionally, chemical classes of aromatic and amino-acid compounds were disrupted, together with Krebs cycle intermediates, lipids and phospholipids. From variable importance in projection (VIP) analyses, the Warburg effect, citric acid cycle, gluconeogenesis and transfer of acetyl groups into mitochondria appeared to be possible pathways involved in the metabolic alterations observed in Klf10 KO mice. These studies have revealed essential roles for Klf10 in regulating multiple metabolic pathways whose alterations may underlie the observed skeletal muscle defects as well as other diseases.
Decreasing Significance of Early Allograft Dysfunction with Rising Use of Nonconventional Donors
Ohara, Stephanie, Macdonough, Elizabeth , Egbert, Lena K. , Brooks, Abigail , Mathur, Amit K. , Aqel, Bashar , Reddy, Kunam S. , Jadlowiec, Caroline C. , Egbert, Lena, Mathur, Amit , Jadlowiec, Caroline , Lizaola‐Mayo, Blanca , Aqel, Bashar A.

Mayo Clinic

Medicina | June 17, 2022 | Volume: 58 | Issue: 6 | Pages: 821

10.3390/medicina58060821 | PMID 35744084 Get It

Background and Objectives: Early allograft dysfunction (EAD) is considered a surrogate marker for adverse post-liver transplant (LT) outcomes. With the increasing use of nonconventional donors, EAD has become a more frequent occurrence. Given this background, we aimed to assess the prevalence and impact of EAD in an updated cohort inclusive of both conventional and nonconventional liver allografts. Materials and Methods: Perioperative and one-year outcomes were assessed for a total of 611 LT recipients with and without EAD from Mayo Clinic Arizona. EAD was defined as the presence of one or more of the following: bilirubin > 10 mg/dL on day 7, INR > 1.6 on day 7, or ALT and/or AST > 2000 IU/L within the first 7 days of LT. Results: Within this cohort, 31.8% of grafts (n = 194) came from donation after circulatory death (DCD) donors, 17.7% (n = 108) were nationally shared, 16.4% (n = 100) were allocated as post-cross clamp, and 8.7% contained moderate steatosis. EAD was observed in 52.2% (n = 321) of grafts in the study cohort (79% in DCD grafts and 40% in DBD grafts). EAD grafts had higher donor risk index (DRI) scores (1.9 vs. 1.6, p < 0.0001), were more likely to come from DCD donors (48% vs. 13.8%, p < 0.0001), were regionally allocated (p = 0.003), and had higher cold ischemia times (median 6.0 vs. 5.5 h, p = 0.001). Primary nonfunction events were rare in both groups (1.3% vs. 0.3%, p = 0.22). Post-LT acute kidney injury occurred at a similar frequency in recipients with and without EAD (43.6% vs. 30.3%, p = 0.41), and there were no differences in ICU (median 2 vs. 1 day, p = 0.60) or hospital (6 vs. 5 days, p = 0.24) length of stay. For DCD grafts, the rate of ischemic cholangiopathy was similar in the two groups (14.9% EAD vs. 17.5% no EAD, p = 0.69). One-year patient survival for grafts with and without EAD was 96.0% and 94.1% (HR 1.2, 95% CI 0.7–1.8; p = 0.54); one-year graft survival was 92.5% and 92.1% (HR 1.0, 95% CI 0.7–1.5; p = 0.88). Conclusions: In this cohort, EAD occurred in 52% of grafts. The occurrence of EAD, however, did not portend inferior outcomes. Compared to those without EAD, recipients with EAD had similar post-operative outcomes, as well as one-year patient and graft survival. EAD should be managed supportively and should not be viewed as a deterrent to utilization of non-ideal grafts.
Hyperinsulinemia Is Highly Associated With Markers of Hepatocytic Senescence in Two Independent Cohorts
Meijnikman, Abraham S. , Olden, Casper C. van , Aydin, Ömrüm , Herrema, Hilde , Kamińska, Dorota , Lappa, Dimitra , Tremaroli, Valentina , Olofsson, Louise E. , Brauw, Maurits de, Verheij, Joanne , Schwartz, Thue W. , Bäckhed, Fredrik , Kirkland, James L. , Kuipers, Folkert , Nieuwdorp, Max , Groen, Albert K., Pajukanta, Päivi , Groen, Albert K , Meijnikman, Abraham Stijn , Männistö, Ville , Laar, Arnold W. J. M. van de , Gerdes, Victor E. A. , NIELSEN, JENS KVIST , Pihlajamäki, Jussi , Tchkonia, Tamar

Mayo Clinic

Diabetes | June 17, 2022 | Volume: 71 | Issue: 9 | Pages: 1929-1936

10.2337/db21-1076 | PMID 35713877 Get It

Cellular senescence is an essentially irreversible growth arrest that occurs in response to various cellular stressors and may contribute to development of type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). In this article, we investigated whether chronically elevated insulin levels are associated with cellular senescence in the human liver. In 107 individuals undergoing bariatric surgery, hepatic senescence markers were assessed by immunohistochemistry as well as transcriptomics. A subset of 180 participants from the ongoing Finnish Kuopio OBesity Surgery (KOBS) study was used as validation cohort. We found plasma insulin to be highly associated with various markers of cellular senescence in liver tissue. The liver transcriptome of individuals with high insulin revealed significant upregulation of several genes associated with senescence: p21, TGFβ, PI3K, HLA-G, IL8, p38, Ras, and E2F. Insulin associated with hepatic senescence independently of NAFLD and plasma glucose. By using transcriptomic data from the KOBS study, we could validate the association of insulin with p21 in the liver. Our results support a potential role for hyperinsulinemia in induction of cellular senescence in the liver. These findings suggest possible benefits of lowering insulin levels in obese individuals with insulin resistance.
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
Thompson, Kevin J. , Leon‐Ferre, Roberto A. , Zahrieh, David , Metzger, Filho Otto, Sikov, William M. , Liu, Minetta C. , Carter, Jodi M. , Klee, Eric W. , Weinshilboum, Richard M. , Wang, Liewei , Zahrieh, David M. , Ingle, James N. , Goetz, Matthew P , Kalari, Krishna R , Thompson, Kevin J , Carter, Jodi , Sinnwell, Jason P. , Suman, Vera J. , Asad, Sarah , Stover, Daniel G. , Carey, Lisa A. , Weinshilboum, Richard M. , Boughey, Judy C. , Couch, Fergus J. , Goetz, Matthew P. , Kalari, Krishna R.

Mayo Clinic

NAR Cancer | June 17, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/narcan/zcac018 | PMID 35734391 Get It

Abstract Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low overall survival rates and high molecular heterogeneity; therefore, few targeted therapies are available. The luminal androgen receptor (LAR) is the most consistently identified TNBC subtype, but the clinical utility has yet to be established. Here, we constructed a novel genomic classifier, LAR-Sig, that distinguishes the LAR subtype from other TNBC subtypes and provide evidence that it is a clinically distinct disease. A meta-analysis of seven TNBC datasets (n = 1086 samples) from neoadjuvant clinical trials demonstrated that LAR patients have significantly reduced response (pCR) rates than non-LAR TNBC patients (odds ratio = 2.11, 95% CI: 1.33, 2.89). Moreover, deconvolution of the tumor microenvironment confirmed an enrichment of luminal epithelium corresponding with a decrease in basal and myoepithelium in LAR TNBC tumors. Increased immunosuppression in LAR patients may lead to a decreased presence of cycling T-cells and plasma cells. While, an increased presence of myofibroblast-like cancer-associated cells may impede drug delivery and treatment. In summary, the lower levels of tumor infiltrating lymphocytes (TILs), reduced immune activity in the micro-environment, and lower pCR rates after NAC, suggest that new therapeutic strategies for the LAR TNBC subtype need to be developed.
Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors
Schuelke, Matthew , Gundelach, Justin H. , Scott, Karen J. , Samson, Adel , Melcher, Alan , Vile, Richard G. , Bram, Richard J. , Schuelke, Matthew R, Melcher, Alan A , Coffey, Matt C. , West, Emma J. , Johnson, Derek R.

Mayo Clinic

Neuro-Oncology Advances | June 17, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac085 | PMID 35821679 Get It

Abstract Background Brain tumors are the leading cause of cancer death for pediatric patients. Pelareorep, an immunomodulatory oncolytic reovirus, has intravenous efficacy in preclinical glioma models when preconditioned with GM-CSF (sargramostim). We report a phase I trial with the primary goal of evaluating the safety of sargramostim/pelareorep in pediatric patients with recurrent or refractory high-grade brain tumors and a secondary goal of characterizing immunologic responses. Methods The trial was open to pediatric patients with recurrent or refractory high-grade brain tumors (3 + 3 cohort design). Each cycle included 3 days of subcutaneous sargramostim followed by 2 days of intravenous pelareorep. Laboratory studies and imaging were acquired upon recruitment and periodically thereafter. Results Six patients participated, including three glioblastoma, two diffuse intrinsic pontine glioma, and one medulloblastoma. Two pelareorep dose levels of 3 × 108 and 5 × 108 tissue culture infectious dose 50 (TCID50) were assessed. One patient experienced a dose limiting toxicity of persistent hyponatremia. Common low-grade (1 or 2) adverse events included transient fatigue, hypocalcemia, fever, flu-like symptoms, thrombocytopenia, and leukopenia. High-grade (3 or 4) adverse events included neutropenia, lymphopenia, leukopenia, hypophosphatemia, depressed level of consciousness, and confusion. All patients progressed on therapy after a median of 32.5 days and died a median of 108 days after recruitment. Imaging at progression did not show evidence of pseudoprogression or inflammation. Correlative assays revealed transient but consistent changes in immune cells across patients. Conclusions Sargramostim/pelareorep was administered to pediatric patients with recurrent or refractory high-grade brain tumors. Hyponatremia was the only dose limiting toxicity (DLT), though maximum tolerated dose (MTD) was not determined.
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)
Seegobin, Karan , Li, Zhuo , Wang, Jing , Jiang, Liuyan , Kuhlman, Justin J. , Menke, David M. , Li, Ke , Kharfan‐Dabaja, Mohamed A. , Ayala, Ernesto , Nowakowski, Grzegorz S. , Johnston, Patrick B. , Thompson, Carrie A. , Ansell, Stephen M. , Alhaj Moustafa, Muhamad, Kuhlman, Justin , Menke, David, Kharfan-Dabaja, Mohamed A , Iqbal, Madiha , Habermann, Thomas , Witzig, T.E. , Thompson, Carrie, Ansell, Stephen M , Moustafa, Muhamad Alhaj , Majeed, Umair , Iqbal, Madiha , Habermann, Thomas M. , Witzig, Thomas E. , Tun, Han W.

Mayo Clinic

American Journal of Hematology | June 17, 2022 | Volume: 97 | Issue: 9 | Pages: 1150-1158

10.1002/ajh.26635 | PMID 35713565 Get It

Abstract Intravascular lymphoma (IVL) is a rare extranodal non‐Hodgkin lymphoma. We performed a retrospective analysis of 55 IVL patients who were treated at our institution 2003–2018. Median age at diagnosis was 68 years, and 64% were males. The most frequent presenting symptoms were skin rash 43% and weight loss 30%. MRI brain on IVL patients with CNS involvement (CNS‐IVL) showed multifocal involvement in 76% (13/17). 89% (17/19) of non‐CNS‐IVL patients with abnormal FDG‐PET had biopsy of an avid lesion resulting in definitive diagnosis. The top diagnostic biopsy site was the bone marrow (45%). 56% had multiorgan involvement. Based on CNS involvement, 36.5% (20/55) had CNS‐IVL and 63.5% (35/55) had non‐CNS‐IVL. CNS‐IVL group consists of clinically isolated CNS involvement (CNS‐only IVL) (22%;12/55) and mixed clinical CNS and peripheral site involvement (M‐IVL) (14.5%; 8/55). Non‐CNS‐IVL group consists of clinically isolated skin involvement (skin‐only IVL) (9%; 5/55) and peripheral IVL with or without skin involvement (P‐IVL); (54.5%; 30/55). Skin involvement was predominantly in the lower extremities. Pathologically, 89% (48/54) were B‐cell IVL. Rituximab + high‐dose methotrexate‐based regimen were used in 75% (12/16) of CNS‐IVL patients and RCHOP in 60% (17/28) of non‐CNS‐IVL patients. Estimated 5‐year progression free survival (PFS) and overall survival (OS) for the entire cohort were 38.6% and 52%, respectively. Skin‐only IVL was associated with excellent survival. Platelet count <150x10 9 /L, age > 60Y, and treatment without Rituximab were poor prognostic factors. Further research is necessary to identify novel therapies.